FGEN קפיטליזציה חשבונאית FibroGen

FibroGen, Inc. (FGEN) generates revenue through the promotion of an innovative anemia drug for renal failure in collaboration with major partners. The market trend of the asset illustrated on this price chart is at the -0.02 level. The operating model relies on external contractors for testing and logistics, which frees up resources for fibrosis research. However, failures with the primary drug triggered a price collapse and the threat of delisting due to a shortage of funds.

Investors are searching FibroGen, Inc. (FGEN) financial statements for fundamental pillars to assess the real value of its assets. Book capitalization measures the business's asset coverage, and analyzing the level of equity based on book value allows for tracking the burn rate of funds allocated to the R&D pipeline, which is critical in the absence of stable revenue and amid high clinical trial risks.